全文获取类型
| 收费全文 | 204197篇 |
| 免费 | 36360篇 |
| 国内免费 | 2520篇 |
专业分类
| 耳鼻咽喉 | 5623篇 |
| 儿科学 | 6806篇 |
| 妇产科学 | 3449篇 |
| 基础医学 | 10591篇 |
| 口腔科学 | 2434篇 |
| 临床医学 | 32540篇 |
| 内科学 | 57608篇 |
| 皮肤病学 | 8170篇 |
| 神经病学 | 19455篇 |
| 特种医学 | 8413篇 |
| 外科学 | 49769篇 |
| 综合类 | 1040篇 |
| 现状与发展 | 72篇 |
| 一般理论 | 57篇 |
| 预防医学 | 12592篇 |
| 眼科学 | 4574篇 |
| 药学 | 4976篇 |
| 1篇 | |
| 中国医学 | 59篇 |
| 肿瘤学 | 14848篇 |
出版年
| 2024年 | 709篇 |
| 2023年 | 5023篇 |
| 2022年 | 1607篇 |
| 2021年 | 4181篇 |
| 2020年 | 6568篇 |
| 2019年 | 3176篇 |
| 2018年 | 8582篇 |
| 2017年 | 8174篇 |
| 2016年 | 9319篇 |
| 2015年 | 9491篇 |
| 2014年 | 17041篇 |
| 2013年 | 17872篇 |
| 2012年 | 9132篇 |
| 2011年 | 9229篇 |
| 2010年 | 12298篇 |
| 2009年 | 15879篇 |
| 2008年 | 9050篇 |
| 2007年 | 7518篇 |
| 2006年 | 9886篇 |
| 2005年 | 7100篇 |
| 2004年 | 6119篇 |
| 2003年 | 4970篇 |
| 2002年 | 4873篇 |
| 2001年 | 4655篇 |
| 2000年 | 3852篇 |
| 1999年 | 4043篇 |
| 1998年 | 4252篇 |
| 1997年 | 3952篇 |
| 1996年 | 3819篇 |
| 1995年 | 3698篇 |
| 1994年 | 2356篇 |
| 1993年 | 1962篇 |
| 1992年 | 1937篇 |
| 1991年 | 1923篇 |
| 1990年 | 1585篇 |
| 1989年 | 1666篇 |
| 1988年 | 1468篇 |
| 1987年 | 1264篇 |
| 1986年 | 1298篇 |
| 1985年 | 1166篇 |
| 1984年 | 929篇 |
| 1983年 | 848篇 |
| 1982年 | 778篇 |
| 1981年 | 643篇 |
| 1980年 | 584篇 |
| 1979年 | 561篇 |
| 1978年 | 577篇 |
| 1977年 | 596篇 |
| 1975年 | 462篇 |
| 1972年 | 507篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
91.
92.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
93.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
94.
95.
96.
Martina A. Steurer Jean Costello Rebecca J. Baer Scott P. Oltman Sky K. Feuer Tania Pacheco-Werner Elizabeth Rogers Marta M. Jankowska Jessica Block Molly McCarthy Matthew S. Pantell Christina Chambers Kelli K. Ryckman Laura L. Jelliffe-Pawlowski 《Paediatric and perinatal epidemiology》2020,34(2):130-138
97.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献98.
99.
Juliette A. Loncaster MD FRCR Ernest Allan 《Photodiagnosis and Photodynamic Therapy》2006,3(2):134-137
Gorlin syndrome (naevoid basal cell carcinoma syndrome) is a genetically linked disorder characterized by the development of multiple basal cell carcinomas (BCCs) throughout life. Cumulative surgery, cryotherapy and other conventional interventions can result in significant disfigurement by middle age. Radiotherapy is contra-indicated because the mutated gene underlying the syndrome, ‘PTCH’, increases sensitivity to ionising radiation, so there is significant likelihood of inducing further tumours in and around the irradiated area. Photodynamic therapy offers a non-invasive treatment option for patients with this condition, with the added advantage of causing minimal scarring. 相似文献
100.